{"disease":{"id":"congenital-erythropoietic-porphyria-cep","name":"congenital erythropoietic porphyria cep"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07024316","title":"A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Atlas Molecular Pharma","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}